Company news

Axsome Therapeutics, Inc. news in 2023

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

December 10, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

December 6, 2023

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

November 21, 2023

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

November 1, 2023

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

October 23, 2023

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

October 10, 2023

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

October 9, 2023

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

October 1, 2023

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

September 20, 2023

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

September 6, 2023

Axsome Therapeutics to Present at Three Upcoming Investor Conferences

September 4, 2023

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

July 11, 2023

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

July 6, 2023

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

June 29, 2023

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

June 27, 2023

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

June 26, 2023

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

May 31, 2023

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 29, 2023

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

May 7, 2023

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

May 2, 2023

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

April 30, 2023

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academ...

April 20, 2023

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 13, 2023

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

April 12, 2023

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

February 28, 2023

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 26, 2023

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

February 21, 2023

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

January 30, 2023

Calls in 2023

Decks in 2023